查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534919

类风湿性关节炎市场：现况分析与预测（2024-2032）

Rheumatoid Arthritis Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 137 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

类风湿性关节炎（RA）是一种慢性发炎性疾病，主要影响关节，可导致疼痛性肿胀、僵硬、关节畸形和糜烂。这是一种自体免疫疾病，免疫系统错误地攻击身体组织。类风湿性关节炎也会影响其他器官，包括皮肤、眼睛、肺、心臟和血管。这种疾病多发生在30岁至60岁之间，女性比男性更容易受到影响。随着世界人口老化，RA 的盛行率不断增加。随着人们寿命的延长，与年龄相关的疾病的盛行率也会增加，包括 RA 等自体免疫疾病。例如，根据 Census.gov 的资料，65 岁及以上的美国人数量预计将增加 47%，从2022年的 5,800 万增加到2050年的 8,200 万人。到2050年，该年龄层人口占总人口的比例预计也将从17%上升至23%。

随着类风湿关节炎盛行率的上升、认识和诊断的提高是市场成长的主要驱动力，类风湿关节炎市场预计将稳定成长 7.5%左右。根据美国疾病管制与预防中心（CDC）的资料，截至2021年，美国约有 130 万成年人患有 RA。此外，诊断方法的改进以及生物製剂和标靶合成缓解病情抗风湿药物（DMARD）的开发也增强了 RA 的管理。这些进步有助于改善患者治疗效果并提高诊断率。

依给药途径，市场分为口服药物及肠胃外药物。其中，口服製剂近年来已风靡市场。口服药物通常比肠胃外治疗更容易施用。患者可以在家中服用口服药物，无需医疗保健专业人员，增加了便利性和依从性。这对于治疗 RA 等慢性疾病尤其重要，长期坚持用药非常重要。

依药物类别划分，市场分为缓解疾病抗风湿药（DMARD）、非类固醇类抗发炎药（NSAID）、皮质类固醇、降尿酸药物等。缓解病情抗风湿药物（DMARD）对类风湿性关节炎治疗市场的收入贡献显着，预计在预测期内将大幅成长。这一成长的推动因素包括人们对DMARD 益处的认识不断提高、类风湿关节炎患病率不断上升、全球肥胖和超重人数不断增加，以及DMARD 作为治疗类风湿关节炎的一线药物越来越受欢迎。这些因素共同增加了对 DMARD 的需求并推动市场向前发展。

根据销售管道，市场分为处方药和非处方药。全球市场细分 在医药市场中，处方药占最大占有率。这项优点归功于处方药的好处，例如确保患者服用正确的剂量、最大限度地减少副作用的风险以及防止潜在的药物滥用。相反，场外交易（OTC）行业预计在预测期内将以最快的速度成长。这种成长是由直接购买非处方药的便利性以及这些药物的持续创新和进步所推动的。

为了更了解类风湿性关节炎的市场介绍，市场有北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区）、亚太地区（中国，该分析基于世界其他地区（日本、印度、亚太其他地区）和世界其他地区的全球存在。在目前2023年的情况下，北美占据市场主导地位。这一优势归因于推动该地区 RA 药物需求和开发的多种因素，包括高可支配收入、先进的医疗基础设施和不断提高的意识。市场上营运的主要公司包括UCB S.A.、F. HOFFMANN-LA ROCHE LTD、Pfizer Inc.、ABBVIE INC.、Novartis AG、Eli Lilly and Company、Teva Pharmaceuticals, Inc.、BRISTOL-MYERS SQUIBB COMPANY、Merck &Co.。

目录

第1章 市场介绍

  • 市场定义
  • 主要目的
  • 利害关係人
  • 限制

第2章 研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第3章 执行摘要

  • 行业概况
  • 依细分市场进行预测
    • 市场成长的力量
  • 区域展望

第4章 市场动态

  • 促进因素
  • 机会
  • 抑制因素
  • 趋势
  • PESTEL 分析
  • 需求方分析
  • 供给面分析
    • 併购
    • 投资场景
    • 产业洞察：主要新创公司及其独特策略

第5章 价格分析

  • 区域价格分析
  • 影响价格的因素

第6章 全球类风湿性关节炎市场收入，2022-2032

第7章 依给药途径细分市场

  • 口服
  • 非口服

第8章 依药物类别细分市场

  • 缓解疾病抗风湿药物（DMARD）
  • 非类固醇类抗发炎药（NSAID）
  • 皮质类固醇
  • 降尿酸药物
  • 其他

第9章 依销售管道细分的市场

  • 处方药
  • 非处方药

第10章 依地区划分的市场分析

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区

第11章 价值链分析

  • 进入市场的公司名单

第12章 竞争态势

  • 竞争对手仪表板
  • 竞争市场定位分析
  • 波特五力分析

第13章 公司简介

  • UCB SA
    • 公司概况
    • 主要财务状况
    • SWOT分析
    • 产品组合
    • 近期趋势
  • F. HOFFMANN-LA ROCHE LTD
  • Pfizer Inc
  • ABBVIE INC.
  • Novartis AG
  • Eli Lilly and Company
  • Teva Pharmaceuticals, Inc.
  • BRISTOL-MYERS SQUIBB COMPANY
  • Merck & Co., Inc.
  • JOHNSON & JOHNSON

第14章 缩写与假设

第15章 附录

简介目录
Product Code: UMHE212918

Rheumatoid Arthritis (RA) is a chronic inflammatory disorder primarily affecting joints, leading to painful swelling, stiffness, and potential joint deformity and erosion. It is an autoimmune condition where the immune system mistakenly attacks the body's tissues. RA can also affect other systems, including the skin, eyes, lungs, heart, and blood vessels. This disease predominantly impacts individuals between the ages of 30 and 60, with women being more commonly affected than men. The prevalence of RA is increasing with the aging global population. As people live longer, the incidence of age-related conditions, including autoimmune diseases like RA, rises. For instance, as per the data of Census.gov, The number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% increase. This age group's share of the total population is also expected to rise from 17% to 23% by 2050.

The Rheumatoid Arthritis Market is expected to grow at a steady rate of around 7.5% due to rising prevalence of rheumatoid Arthritis, and increased awareness and diagnosis acting as major drivers for the growth of the market. According to the Centers for Disease Control and Prevention (CDC), approximately 1.3 million adults in the United States were living with RA as of 2021. Further, improved diagnostic methods and the development of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) have enhanced the management of RA. These advancements contribute to better patient outcomes and increased diagnosis rates.

Based on the route of administration, the market is segmented into oral and parenteral. Among these, the oral segment has dominated the market in recent years. Oral medications are generally easier to administer compared to parenteral treatments. Patients can take oral drugs at home without the need for a healthcare professional, which enhances convenience and compliance. This is particularly important for managing a chronic condition like RA, where long-term adherence to treatment is crucial.

Based on the Drug Class, the market is segmented into Disease-modifying Anti-rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Uric Acid Drugs, and Others. Disease-modifying antirheumatic drugs (DMARDs) are the primary contributors to revenue in the rheumatoid arthritis treatment market, and their growth is expected to be substantial over the forecast period. This growth is driven by increased awareness of the benefits of DMARDs, a rising prevalence of rheumatoid arthritis, a growing global population of obese and overweight individuals, and the widespread adoption of DMARDs as the first-line treatment for rheumatoid arthritis. These factors collectively enhance the demand for DMARDs, propelling the market forward.

Based on the sales channel, the market is segmented into Prescription-based Drugs and Over-the-counter Drugs. The prescription-based drug segment holds the largest share in the global rheumatoid arthritis drugs market. This dominance is attributed to the benefits of prescription medications, such as ensuring patients receive the correct dosage, minimizing the risk of side effects, and preventing potential misuse of drugs. Conversely, the over-the-counter (OTC) drug segment is projected to grow at the fastest rate during the forecast period. This growth is driven by the convenience of purchasing OTC drugs directly and the continuous innovations and advancements in these medications.

For a better understanding of the market adoption of Rheumatoid Arthritis, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2023. This dominance can be attributed to several factors that drive the demand and development of RA therapeutics in the region, such as high disposable income, advanced healthcare infrastructure, and rising awareness. Some of the major players operating in the market include UCB S.A., F. HOFFMANN-LA ROCHE LTD, Pfizer Inc, ABBVIE INC., Novartis AG, Eli Lilly and Company, Teva Pharmaceuticals, Inc., BRISTOL-MYERS SQUIBB COMPANY, Merck & Co., Inc., and JOHNSON & JOHNSON.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Rheumatoid Arthritis Market
  • 2.2. Research Methodology of the Rheumatoid Arthritis Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL RHEUMATOID ARTHRITIS MARKET REVENUE (USD BN), 2022-2032F

7.MARKET SEGMENT BY ROUTE OF ADMINISTRATION

  • 7.1. Oral
  • 7.2. Parenteral

8.MARKET SEGMENT BY DRUG CLASS

  • 8.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
  • 8.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 8.3. Corticosteroids
  • 8.4. Uric Acid Drugs
  • 8.5. Others

9.MARKET SEGMENT BY SALES CHANNEL

  • 9.1. Prescription-based Drugs
  • 9.2. Over-the-counter Drugs

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

  • 11.1. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILED

  • 13.1. UCB S.A.
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. F. HOFFMANN-LA ROCHE LTD
  • 13.3. Pfizer Inc
  • 13.4. ABBVIE INC.
  • 13.5. Novartis AG
  • 13.6. Eli Lilly and Company
  • 13.7. Teva Pharmaceuticals, Inc.
  • 13.8. BRISTOL-MYERS SQUIBB COMPANY
  • 13.9. Merck & Co., Inc.
  • 13.10. JOHNSON & JOHNSON

14.ACRONYMS & ASSUMPTION

15.ANNEXURE